Rhabdomyosarcoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: RHB003 MIFTS: 65	Rhabdomyosarcoma Categories: Bone diseases, Cancer diseases, Genetic diseases, Muscle diseases, Neuronal diseases, Rare diseases, Respiratory diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Rhabdomyosarcoma

MalaCards integrated aliases for Rhabdomyosarcoma:

Name: Rhabdomyosarcoma ¹¹ ⁵⁸ ⁷⁵ ²⁸ ⁵³ ⁵ ⁴³ ¹⁴ ¹⁶ ⁷¹

Characteristics:

Inheritance:

Multigenic/multifactorial ⁵⁸

Prevelance:

1-9/1000000 (Europe) ⁵⁸

Age Of Onset:

Childhood ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases Genetic diseases
Anatomical: Neuronal diseases Muscle diseases Bone diseases Respiratory diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Neoplasms

Malignant neoplasms of mesothelial and soft tissue

Malignant neoplasm of other connective and soft tissue

Malignant neoplasm: Connective and soft tissue, unspecified

Orphanet: ⁵⁸

Rare neurological diseases

External Ids:

Disease Ontology ¹¹ DOID:3247

MeSH ⁴³ D012208

NCIt ⁴⁹ C3359

SNOMED-CT ⁶⁸ 302847003

MESH via Orphanet ⁴⁴ D012208

ICD10 via Orphanet ³² C49.9

UMLS via Orphanet ⁷² C0035412

Orphanet ⁵⁸ ORPHA780

EFO ¹⁶ EFO_0002918

UMLS ⁷¹ C0035412

Sources

Summaries for Rhabdomyosarcoma

Orphanet: ⁵⁸ A malignant soft tissue tumor which develops from cells of striated muscle. It is the most common form of tumor found in children and adolescents.

MalaCards based summary: Rhabdomyosarcoma is related to embryonal rhabdomyosarcoma and rhabdomyosarcoma 2. An important gene associated with Rhabdomyosarcoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Disease and Prolactin Signaling. The drugs Sargramostim and Idarubicin have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, lymph node and t cells, and related phenotypes are homeostasis/metabolism and neoplasm

Disease Ontology: ¹¹ A skeletal muscle cancer that arise from skeletal muscle progenitors.

Wikipedia: ⁷⁵ Rhabdomyosarcoma (RMS) is a highly aggressive form of cancer that develops from mesenchymal cells that... more...

Sources

Related Diseases for Rhabdomyosarcoma

Diseases in the Rhabdomyosarcoma family:

Rhabdomyosarcoma 2

Diseases related to Rhabdomyosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1127)

#	Related Disease	Score	Top Affiliating Genes
1	embryonal rhabdomyosarcoma	33.7	TP53 NF1 HRAS DICER1 ALK
2	rhabdomyosarcoma 2	33.6	TP53 RMST NF1 ALK
3	pleomorphic rhabdomyosarcoma	33.0	TP53 NF1 HRAS
4	mismatch repair cancer syndrome 1	32.7	PTEN PMS2 MSH6 MSH2
5	li-fraumeni syndrome	32.3	TP53 PTEN PMS2 NF1 MSH6 MSH2
6	large cell carcinoma with rhabdoid phenotype	32.2	TP53 HRAS
7	costello syndrome	31.9	NF1 LRRC56 HRAS
8	neurofibromatosis	31.7	TP53 PTEN PMS2 NF1 MSH6 MSH2
9	mesenchymal cell neoplasm	31.6	TP53 NF1 ALK
10	carcinosarcoma	31.5	TP53 PTEN HRAS
11	cowden syndrome 1	31.5	TP53 PTEN PMS2 NF1 MSH6 MSH2
12	ewing sarcoma	31.4	TP53 NF1 BRCA1 ALK
13	neuroblastoma	31.4	TP53 PTEN NF1 MIR29C HRAS DICER1
14	blastoma	31.3	TP53 HRAS DICER1
15	liposarcoma	31.3	TP53 PTEN NF1 MSH2
16	adenoma	31.3	TP53 PMS2 MSH6 MSH2 HRAS
17	connective tissue benign neoplasm	31.3	TP53 NF1 ALK
18	lymphangioma	31.2	TP53 PMS2 MSH6 MSH2 HRAS
19	wilms tumor 1	31.2	TP53 PTEN NF1 HRAS DICER1 BRCA2
20	muscle cancer	31.2	TP53 RMST PTEN NF1 HRAS ALK
21	leiomyosarcoma	31.2	TP53 NF1 BRCA1
22	dicer1 syndrome	31.1	TP53 NF1 DICER1
23	neurofibromatosis, type i	31.1	TP53 SDHA PTEN PMS2 NF1 MSH6
24	skeletal muscle cancer	31.1	TP53 RMST NF1 HRAS DICER1 ALK
25	adenocarcinoma	31.0	TP53 PTEN MSH6 MSH2 HRAS BRCA2
26	medulloblastoma	31.0	TP53 PTEN NF1 MSH6 MSH2 HRAS
27	small cell carcinoma	31.0	TP53 PTEN ALK
28	brain cancer	31.0	TP53 PTEN PMS2 NF1 MSH6 MSH2
29	endometrial adenocarcinoma	31.0	TP53 PTEN PMS2 MSH6 MSH2
30	colorectal adenocarcinoma	30.9	TP53 PTEN PMS2 MSH6 MSH2 HRAS
31	hematologic cancer	30.9	MSH2 MIR29C HRAS CBL ALK
32	uterine carcinosarcoma	30.9	TP53 PTEN PMS2 MSH6 MSH2 LRRC56
33	lynch syndrome 1	30.8	PMS2 MSH6 MSH2
34	mixed cell type cancer	30.8	TP53 PTEN HRAS BRCA1
35	aplastic anemia	30.8	TP53 MSH6 MSH2 BRCA2 BRCA1
36	colonic benign neoplasm	30.8	TP53 PTEN PMS2 MSH6 MSH2 HRAS
37	basal cell nevus syndrome	30.8	TP53 PTEN NF1 HRAS BRCA2 BRCA1
38	bladder cancer	30.8	TP53 PTEN MSH2 MIR29C LRRC56 HRAS
39	rectal benign neoplasm	30.8	TP53 PMS2 MSH6 MSH2 HRAS
40	desmoid tumor	30.8	TP53 PMS2 MSH6 MSH2 ALK
41	bap1 tumor predisposition syndrome	30.8	TP53 SDHA PTEN PMS2 NF1 MSH6
42	rectum adenocarcinoma	30.8	TP53 PMS2 MSH6 MSH2 HRAS
43	dedifferentiated liposarcoma	30.8	TP53 NF1 ALK
44	ovarian cancer	30.7	TP53 PTEN PMS2 MSH6 MSH2 MIR29C
45	noonan syndrome 1	30.7	TP53 PTEN NF1 LRRC56 HRAS CBL
46	gastrointestinal stromal tumor	30.7	TP53 SDHA PTEN NF1 HRAS ALK
47	neurofibroma	30.7	TP53 PTEN NF1
48	skin benign neoplasm	30.7	TP53 NF1 MSH6 MSH2 HRAS
49	lynch syndrome	30.7	TP53 PTEN PMS2 NF1 MSH6 MSH2
50	rectum cancer	30.7	TP53 MSH6 MSH2 HRAS

Graphical network of the top 20 diseases related to Rhabdomyosarcoma:

Sources

Symptoms & Phenotypes for Rhabdomyosarcoma

MGI Mouse Phenotypes related to Rhabdomyosarcoma:

⁴⁵ (show all 12)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.28	ALK BRCA1 BRCA2 CBL DICER1 HRAS
2	neoplasm	MP:0002006	10.24	ALK BRCA1 BRCA2 DICER1 HRAS MSH2
3	endocrine/exocrine gland	MP:0005379	10.1	ALK BRCA1 BRCA2 CBL DICER1 HRAS
4	muscle	MP:0005369	10.08	BRCA1 CBL DICER1 HRAS MIR206 NF1
5	limbs/digits/tail	MP:0005371	10	BRCA1 BRCA2 CBL DICER1 NF1 PTEN
6	pigmentation	MP:0001186	9.99	ALK BRCA1 CBL NF1 PTEN TP53
7	digestive/alimentary	MP:0005381	9.97	BRCA1 BRCA2 HRAS MSH2 NF1 PMS2
8	respiratory system	MP:0005388	9.97	ALK BRCA1 CBL DICER1 HRAS LRRC56
9	reproductive system	MP:0005389	9.96	ALK BRCA1 BRCA2 CBL DICER1 LRRC56
10	skeleton	MP:0005390	9.9	ALK BRCA1 BRCA2 CBL DICER1 HRAS
11	mortality/aging	MP:0010768	9.83	ALK BRCA1 BRCA2 CBL DICER1 HRAS
12	integument	MP:0010771	9.4	ALK BRCA1 BRCA2 CBL DICER1 HRAS

Sources

Drugs & Therapeutics for Rhabdomyosarcoma

Drugs for Rhabdomyosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 211)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Sargramostim

Approved, Investigational

Phase 3

123774-72-1

Idarubicin

Approved

Phase 3

58957-92-9

42890

Morphine

Approved, Investigational

Phase 3

57-27-2

5288826

Mechlorethamine

Approved, Investigational

Phase 2, Phase 3

51-75-2

4033

Daunorubicin

Approved

Phase 2, Phase 3

20830-81-3

30323

Vinorelbine

Approved, Investigational

Phase 3

71486-22-1

44424639 60780

Dactinomycin

Approved, Investigational

Phase 3

50-76-0

2019 457193

Sirolimus

Approved, Investigational

Phase 3

53123-88-9

5284616 6436030

Irinotecan

Approved, Investigational

Phase 3

97682-44-5, 100286-90-6

60838

Miconazole

Approved, Investigational, Vet_approved

Phase 3

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 3

23593-75-1

2812

Vincristine

Approved, Investigational

Phase 3

2068-78-2, 57-22-7

5978

Etoposide

Approved

Phase 3

33419-42-0

36462

Ifosfamide

Approved

Phase 3

3778-73-2

3690

Carboplatin

Approved

Phase 3

41575-94-4

10339178 38904

Epirubicin

Approved

Phase 3

56420-45-2

41867

Molgramostim

Investigational

Phase 3

99283-10-0

Trofosfamide

Investigational

Phase 3

22089-22-1

65702

Camptothecin

Experimental

Phase 3

7689-03-4

24360

Palifosfamide

Investigational

Phase 3

31645-39-3

100427

Calcium, Dietary

Phase 3

Cactinomycin

Phase 3

topoisomerase I inhibitors

Phase 3

Antifungal Agents

Phase 3

Etoposide phosphate

Phase 3

16760419

Calcium

Nutraceutical

Phase 3

7440-70-2

271

Fludarabine

Approved

Phase 1, Phase 2

75607-67-9, 21679-14-1

30751 657237

Cisplatin

Approved

Phase 2

15663-27-1

2767 5702198 441203

Prednisolone phosphate

Approved, Vet_approved

Phase 2

302-25-0

Prednisolone acetate

Approved, Vet_approved

Phase 2

52-21-1

Prednisolone

Approved, Vet_approved

Phase 2

50-24-8

4894 5755

Etanercept

Approved, Investigational

Phase 2

185243-69-0

Methylprednisolone hemisuccinate

Approved

Phase 2

2921-57-5

1875

Methylprednisolone

Approved, Vet_approved

Phase 2

83-43-2

4159 6741

Trabectedin

Approved, Investigational

Phase 2

114899-77-3

108150

Adenosine

Approved, Investigational

Phase 2

58-61-7

60961

Trastuzumab

Approved, Investigational

Phase 2

180288-69-1

Cobalt

Approved, Experimental, Withdrawn

Phase 2

7440-48-4

104729

Afatinib

Approved

Phase 1, Phase 2

439081-18-2, 850140-72-6

53445376 10184653

Levoleucovorin

Approved, Experimental, Investigational

Phase 2

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Pemetrexed

Approved, Investigational

Phase 2

150399-23-8, 137281-23-3

60843 446556 135565230

Oxaliplatin

Approved, Investigational

Phase 2

61825-94-3

43805 11947679 6857599

Romidepsin

Approved, Investigational

Phase 2

128517-07-7

5352062

Indinavir

Approved

Phase 2

150378-17-9

5362440

Topotecan

Approved, Investigational

Phase 2

123948-87-8, 119413-54-6

60699 60700

Picropodophyllin

Approved, Investigational

Phase 2

518-28-5, 477-47-4

10607 72435

Melphalan

Approved

Phase 2

148-82-3

4053 460612

Ivosidenib

Approved, Investigational

Phase 2

1448347-49-6

78140854 71657455

Talazoparib

Approved, Investigational

Phase 1, Phase 2

1207456-01-6

135565082

Thiotepa

Approved, Investigational

Phase 2

52-24-4

5453

Interventional clinical trials:

(show top 50) (show all 207)

#	Name	Status	NCT ID	Phase	Drugs
1	EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children	Unknown status	NCT00339118	Phase 4	doxorubicin, cytoxan
2	An Open Label, Single Centre, Single Arm, Prospective Feasibility Study Evaluating the Effectiveness of Near-infrared Fluorescence (NIRF) Using Indo-cyanine Green (ICG) in Minimally Invasive Paediatric Oncology Surgery (MIS)	Recruiting	NCT04854018	Phase 4	Indocyanine green
3	A Protocol For Nonmetastatic Rhabdomyosarcoma [RMS-2005]	Unknown status	NCT00379457	Phase 3	carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate;vinorelbine tartrate
4	Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas	Unknown status	NCT00334854	Phase 3	doxorubicin hydrochloride;ifosfamide
5	Randomized Study of Vincristine, Actinomycin-D, and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine, Topotecan and Cyclophosphamide for Patients With Intermediate Risk Rhabdomyosarcoma	Completed	NCT00003958	Phase 3	vincristine sulfate;cyclophosphamide;topotecan hydrochloride
6	Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma	Completed	NCT00075582	Phase 3	dactinomycin;cyclophosphamide;vincristine sulfate
7	A Randomised Phase-III Trial of the Cooperative Weichteilsarkom Study Group (CWS) for Localised High-risk Rhabdomyosarcoma and Localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in Children, Adolescents, and Young Adults	Completed	NCT00876031	Phase 3	trofosfamide, idarubicin, etoposide
8	A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation	Completed	NCT01305200	Phase 3	supersaturated calcium phosphate rinse
9	MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood	Completed	NCT00002898	Phase 3	carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
10	Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients With High-Risk Rhabdomyosarcoma	Completed	NCT00354744	Phase 3	cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;irinotecan hydrochloride;vincristine sulfate
11	Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age	Completed	NCT00346164	Phase 3	doxorubicin hydrochloride;ifosfamide
12	Actinomycin D and Vincristine With or Without Radiation Therapy, for Newly Diagnosed Patients With Low-Risk Rhabdomyosarcoma or Undifferentiated Sarcoma: IRS-V Protocol	Completed	NCT00002995	Phase 3	cyclophosphamide;vincristine sulfate
13	A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients With High Risk Rhabdomyosarcoma (HR-RMS)	Recruiting	NCT04994132	Phase 3	Cyclophosphamide;Vincristine Sulfate;Vinorelbine Tartrate
14	A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma	Recruiting	NCT05304585	Phase 3	Cyclophosphamide;Vincristine
15	Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine and Irinotecan (VI) for Patients With Intermediate-Risk Rhabdomyosarcoma (RMS)	Active, not recruiting	NCT00354835	Phase 3	Irinotecan Hydrochloride;Cyclophosphamide;Vincristine Sulfate
16	Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)	Active, not recruiting	NCT02180867	Phase 2, Phase 3	Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
17	A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)	Suspended	NCT02567435	Phase 3	Cyclophosphamide;Irinotecan Hydrochloride;Temsirolimus;Vincristine Sulfate;Vinorelbine
18	Rhabdomyosarcoma and Malignant Soft Tissue Tumours of Childhood	Terminated	NCT00162695	Phase 3	Ifosfamide, oncovin, actinomycine D, epirubicine, carboplatinum, etoposide
19	Efficacy and Safety of Radiotherapy Combined With Apatinib Mesylate in the Treatment of Rhabdomyosarcoma in Children	Unknown status	NCT03868852	Phase 1, Phase 2	Apatinib mesylate tablets
20	Phase II Trial of VAC2.2/VA Therapy for Low-Risk B Group Patients With Rhabdomyosarcoma	Unknown status	NCT00245089	Phase 2	cyclophosphamide;vincristine sulfate
21	Phase II Trial of Short VAC1.2 Therapy for Low-Risk A Group Patients With Rhabdomyosarcoma	Unknown status	NCT00245141	Phase 2	cyclophosphamide;vincristine sulfate
22	Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas	Unknown status	NCT01216839	Phase 2	Everolimus
23	Pilot Study of Expanded , Activated Haploidentical Natural Killer Cell Infusions for Sarcomas	Unknown status	NCT02409576	Phase 1, Phase 2
24	Hypofractionated 5x5 Gy Radiotherapy With Sequential Doxorubicin and Ifosfamide-based Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall	Unknown status	NCT03651375	Phase 2	Sequential chemotherapy - 3 courses of AI
25	Haploidentical Stem Cell Transplantation Followed by NK Cell Infusion in Patients With High-risk Solid Tumors Who Failed Autologous Stem Cell Transplantation	Unknown status	NCT01807468	Phase 2
26	Phase II Study of Vinorelbine + Cyclofosfamide Association Among Patients Reached of Refractory Tumours or in Relapse	Unknown status	NCT00180947	Phase 2	Vinorelbine, cyclofosfamide
27	A Randomized Phase II Trial of Bevacizumab (Avastin) and Temsirolimus (Torisel) in Combination With Intravenous Vinorelbine and Cyclophosphamide in Patients With Recurrent/Refractory Rhabdomyosarcoma	Completed	NCT01222715	Phase 2	Cyclophosphamide;Temsirolimus;Vinorelbine Tartrate
28	A Groupwide Randomized Phase II Window Study of Two Different Schedules of Irinotecan in Combination With Vincristine And Pilot Assessment of Safety and Efficacy of Tirapazamine Combined With Multiagent Chemotherapy for First Relapse or Progressive Disease in Rhabdomyosarcoma and Related Tumors	Completed	NCT00025363	Phase 2	vincristine sulfate;irinotecan hydrochloride;cyclophosphamide;doxorubicin hydrochloride;ifosfamide;etoposide;tirapazamine
29	Phase II Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Children and Young Adults With Refractory Solid Tumors	Completed	NCT00331643	Phase 2	ixabepilone
30	A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody NSC # 742460]) in Combination With Intensive Multi-agent Interval Compressed Therapy for Patients With High-Risk Rhabdomyosarcoma	Completed	NCT01055314	Phase 2	Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Irinotecan Hydrochloride;Temozolomide;Vincristine Sulfate Liposome
31	A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors	Completed	NCT00831844	Phase 2
32	A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors	Completed	NCT01614795	Phase 2	Temsirolimus
33	An Open-label, Multi-center, Randomized Study of the Safety and Effect on Event-free Survival of Bevacizumab in Combination With Standard Chemotherapy in Childhood and Adolescent Patients With Metastatic Rhabdomyosarcoma and Non-rhabdomyosarcoma Soft Tissue Sarcoma	Completed	NCT00643565	Phase 2	Standard chemotherapy;bevacizumab [Avastin]
34	A Phase 2, Multicenter, Open-label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)	Completed	NCT03441360	Phase 2	Eribulin mesylate
35	A Pilot Study of Tumor Vaccination and R-hIL-7 Following Standard Multimodality Therapy in Patients With High Risk Pediatric Solid Tumors	Completed	NCT00923351	Phase 1, Phase 2	Tumor Purged/CD25 Depleted Lymphocytes;rhIL-7
36	Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation	Completed	NCT00309907	Phase 2	methylprednisolone
37	A Phase 1/2 Single-arm Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan in Children With Refractory or Recurrent Solid Tumors	Completed	NCT03245450	Phase 1, Phase 2	Eribulin mesilate;Irinotecan hydrochloride
38	A Phase II Study Of Trabectedin (ET-743, Yondelis®) in Children With Recurrent Rhabdomyosarcoma, Ewing Sarcoma, or Nonrhabdomyosarcomatous Soft Tissue Sarcomas	Completed	NCT00070109	Phase 2	trabectedin
39	Phase II Trial of Irinotecan in Children With Refractory Solid Tumors	Completed	NCT00004078	Phase 2	irinotecan hydrochloride
40	A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma	Completed	NCT01502410	Phase 2	sorafenib tosylate
41	A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias	Completed	NCT01154816	Phase 2	Alisertib
42	A Phase II Study Of Intravenous DX-8951f (EXATECAN MESYLATE) Administered Daily For Five Days Every Three Weeks To Pediatric Patients With Relapsed Or Refractory Rhabdomyosarcoma	Completed	NCT00055939	Phase 2	exatecan mesylate
43	MMT 98 Study For Metastatic Disease Rhabdomyosarcoma And Other Malignant Soft Tissue Sarcoma Of Childhood	Completed	NCT00025441	Phase 2	carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
44	A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; NSC#: 783609) in Children With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma	Completed	NCT02452554	Phase 2
45	Phase II Study of Neoadjuvant Vincristine, Ifosfamide, Doxorubicin, and AND G-CSF in Children With Advanced Stage Non-Rhabdomyosarcoma Soft Tissue Sarcomas	Completed	NCT00002804	Phase 2	doxorubicin hydrochloride;ifosfamide;mesna;vincristine sulfate
46	New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma	Completed	NCT00001335	Phase 2	ADR-529;Topotecan;G-CSF
47	Phase I/II Open Label, Dose Escalation Trial to Determine the MTD, Safety, PK and Efficacy of Afatinib Monotherapy in Children Aged ≥1 Year to <18 Years With Recurrent/Refractory Neuroectodermal Tumours, Rhabdomyosarcoma and/or Other Solid Tumours With Known ErbB Pathway Deregulation Regardless of Tumour Histology	Completed	NCT02372006	Phase 1, Phase 2	afatinib
48	A Phase II "Up-Front Window Study" of Irinotecan (CPT-11) Followed by Multimodal, Multiagent, Therapy for Selected Children and Adolescents With Newly Diagnosed Stage 4/Clinical Group IV Rhabdomyosarcoma: An IRS-V Study	Completed	NCT00003955	Phase 2	cyclophosphamide;irinotecan hydrochloride;vincristine sulfate
49	A Prospective, Open-Label, Multicenter Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping	Completed	NCT02509598	Phase 2	Tc99m tilmanocept;Vital Blue Dye (optional)
50	International Randomized Phase II Trial of the Combination of Vincristine and Irinotecan With or Without Temozolomide (VI or VIT) in Children and Adults With Refractory or Relapsed Rhabdomyosarcoma	Completed	NCT01355445	Phase 2	Vincristine, Irinotecan;Vincristine, Irinotecan, Temozolomide

Search NIH Clinical Center for Rhabdomyosarcoma

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Cyclophosphamide

Dacarbazine

Etoposide

etoposide phosphate

Melphalan

Melphalan hydrochloride

Vincristine

Vincristine Sulfate

Cochrane evidence based reviews: rhabdomyosarcoma

Sources

Genetic Tests for Rhabdomyosarcoma

Genetic tests related to Rhabdomyosarcoma:

#	Genetic test	Affiliating Genes
1	Rhabdomyosarcoma ²⁸

Sources

Anatomical Context for Rhabdomyosarcoma

Organs/tissues related to Rhabdomyosarcoma:

MalaCards : Skeletal Muscle, Lymph Node, T Cells, Lung, Bone, Bone Marrow, Myeloid

Sources

Publications for Rhabdomyosarcoma

Articles related to Rhabdomyosarcoma:

(show top 50) (show all 11893)

#	Title	Authors	PMID	Year
1	Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534). ⁶² ⁵	Li SQ...Khan J	24124571	2013
2	Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications. ⁶² ⁵	van Gaal JC...Versleijen-Jonkers YM	22184391	2012
3	Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. ⁶² ⁵	Taylor JG...Khan J	19809159	2009
4	MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. ⁵³ ⁶² ⁴⁶	Yan D...Tu L	19710019	2009
5	The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. ⁶² ⁴⁶	Taulli R...Ponzetto C	19620785	2009
6	NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. ⁶² ⁴⁶	Wang H...Guttridge DC	18977326	2008
7	Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family. ⁵³ ⁶²	Sumegi J...Bridge JA	19953635	2010
8	Increased expression of the hedgehog signaling pathway in pediatric solid malignancies. ⁵³ ⁶²	Oue T...Fukuzawa M	20152358	2010
9	Adult-type rhabdomyosarcoma: analysis of 57 cases with clinicopathologic description, identification of 3 morphologic patterns and prognosis. ⁵³ ⁶²	Stock N...Coindre JM	19898221	2009
10	Desensitisation of native and recombinant human urotensin-II receptors. ⁵³ ⁶²	Batuwangala MS...Lambert DG	19680632	2009
11	SNP genotyping of a sclerosing rhabdomyosarcoma: reveals highly aneuploid profile and a specific MDM2/HMGA2 amplification. ⁵³ ⁶²	Bouron-Dal Soglio D...Fournet JC	19454362	2009
12	Prognostic significance of phosphorylated FOXO1 expression in soft tissue sarcoma. ⁵³ ⁶²	Zhang B...Aozasa K	19408047	2009
13	Coexistence of a clear cell adenocarcinoma and an adenosarcoma with a heterologous rhabdomyosarcoma in an endometriotic cyst of the ovary: a case study. ⁵³ ⁶²	Yasuoka H...Nakamura Y	19483627	2009
14	Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. ⁵³ ⁶²	McDermott U...Settleman J	19366796	2009
15	Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. ⁵³ ⁶²	Nanni P...Lollini PL	19372547	2009
16	MyoD and E-protein heterodimers switch rhabdomyosarcoma cells from an arrested myoblast phase to a differentiated state. ⁵³ ⁶²	Yang Z...Tapscott SJ	19299559	2009
17	Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors. ⁵³ ⁶²	Makawita S...Somers GR	18788888	2009
18	The actin-cytoskeleton linker protein ezrin is regulated during osteosarcoma metastasis by PKC. ⁵³ ⁶²	Ren L...Khanna C	19060919	2009
19	WT1 (Wilms tumor 1) peptide immunotherapy for childhood rhabdomyosarcoma: a case report. ⁵³ ⁶²	Ohta H...Ozono K	19206012	2009
20	Characteristic overexpression of the forkhead box transcription factor Foxf1 in Patched-associated tumors. ⁵³ ⁶²	Wendling DS...Kappler R	19020777	2008
21	Pax genes in embryogenesis and oncogenesis. ⁵³ ⁶²	Wang Q...Kumar P	18627422	2008
22	Role of class I human leukocyte antigen molecules in early steps of echovirus infection of rhabdomyosarcoma cells. ⁵³ ⁶²	Chevaliez S...Delpeyroux F	18823925	2008
23	Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype. ⁵³ ⁶²	Heerema-McKenney A...Linn SC	18708938	2008
24	Alterations of RB1 gene in embryonal and alveolar rhabdomyosarcoma: special reference to utility of pRB immunoreactivity in differential diagnosis of rhabdomyosarcoma subtype. ⁵³ ⁶²	Kohashi K...Tsuneyoshi M	18386058	2008
25	Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. ⁵³ ⁶²	Cao L...Helman LJ	18829562	2008
26	Rhabdomyosarcoma subtyping by immunohistochemical assessment of myogenin: tissue array study and review of the literature. ⁵³ ⁶²	Morgenstern DA...Anderson J	18493875	2008
27	Effects of 4E-BP1 expression on hypoxic cell cycle inhibition and tumor cell proliferation and survival. ⁵³ ⁶²	Barnhart BC...Simon MC	18708753	2008
28	A retrovirus-based system to stably silence GDF-8 expression and enhance myogenic differentiation in human rhabdomyosarcoma cells. ⁵³ ⁶²	Yang Z...Tien P	18563849	2008
29	Clinical significance of CXC chemokine receptor-4 and c-Met in childhood rhabdomyosarcoma. ⁵³ ⁶²	Diomedi-Camassei F...Dominici C	18593989	2008
30	A comparative immunohistochemical analysis of small round cell tumors of childhood: utility of peripherin and alpha-internexin as markers for neuroblastomas. ⁵³ ⁶²	Willoughby V...Donner LR	18528283	2008
31	Cisplatin treatment increases survival and expansion of a highly tumorigenic side-population fraction by upregulating VEGF/Flt1 autocrine signaling. ⁵³ ⁶²	Tsuchida R...Malkin D	18332870	2008
32	Nestin expression in different tumours and its relevance to malignant grade. ⁵³ ⁶²	Yang XH...Xiang AP	17873113	2008
33	Detection of FOXO1 (FKHR) gene break-apart by fluorescence in situ hybridization in formalin-fixed, paraffin-embedded alveolar rhabdomyosarcomas and its clinicopathologic correlation. ⁵³ ⁶²	Mehra S...Zhang S	18303411	2008
34	A functional nuclear localization signal in insulin-like growth factor binding protein-6 mediates its nuclear import. ⁵³ ⁶²	Iosef C...Han VK	18039785	2008
35	MDM2 displays differential activities dependent upon the activation status of NFkappaB. ⁵³ ⁶²	Cheney MD...Harris LC	17938575	2008
36	Genetic modeling of Ras-induced human rhabdomyosarcoma. ⁵³ ⁶²	Linardic CM...Counter CM	18413264	2008
37	FGFR1 over-expression in primary rhabdomyosarcoma tumors is associated with hypomethylation of a 5' CpG island and abnormal expression of the AKT1, NOG, and BMP4 genes. ⁵³ ⁶²	Goldstein M...Orr-Urtreger A	17696196	2007
38	Phosphorylation profiles of protein kinases in alveolar and embryonal rhabdomyosarcoma. ⁵³ ⁶²	Cen L...Lin J	17585318	2007
39	Increased fat oxidation and regulation of metabolic genes with ultraendurance exercise. ⁵³ ⁶²	Helge JW...Cotter JD	17488246	2007
40	PAX3 and PAX3-FKHR promote rhabdomyosarcoma cell survival through downregulation of PTEN. ⁵³ ⁶²	Li HG...Kumar P	17350164	2007
41	Evaluation of no-wash calcium assay kits: enabling tools for calcium mobilization. ⁵³ ⁶²	Xin H...Minor LK	17537987	2007
42	Promotion of cancer cell migration: an insulin-like growth factor (IGF)-independent action of IGF-binding protein-6. ⁵³ ⁶²	Fu P...Bach LA	17519236	2007
43	[Adult prostate sarcoma: a report of 6 cases with clinical analysis]. ⁵³ ⁶²	Wang KF...Zhang Y	17725305	2007
44	Friend leukaemia integration-1 expression in malignant and benign tumours: a multiple tumour tissue microarray analysis using polyclonal antibody. ⁵³ ⁶²	Mhawech-Fauceglia P...Mhawech-Fauceglia P	16917000	2007
45	Patched haploinsufficient mouse rhabdomyosarcoma overexpress secreted phosphoprotein 1 and matrix metalloproteinases. ⁵³ ⁶²	De Bortoli M...Kim JY	17467979	2007
46	Smad4 and ERK2 stimulated by transforming growth factor beta1 in rhabdomyosarcoma. ⁵³ ⁶²	Guo H...Bu H	17439748	2007
47	Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models. ⁵³ ⁶²	McDowell HP...Dominici C	17131346	2007
48	Primary osseous rhabdomyosarcoma with focal matrix formation mimicking osteosarcoma. ⁵³ ⁶²	Kordek R...Jesionek-Kupnicka D	17905523	2007
49	Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. ⁵³ ⁶²	Croci S...Lollini PL	18158569	2007
50	Effects of RNAi-mediated Smad4 silencing on growth and apoptosis of human rhabdomyosarcoma cells. ⁵³ ⁶²	Ye L...Bu H	17016646	2006

Sources

Genes for Rhabdomyosarcoma

Genes related to Rhabdomyosarcoma (17 elite genes):

(show top 50) (show all 230)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	TP53	Tumor Protein P53	Protein Coding	449.62	Pathogenic ⁵ Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
2	ALK	ALK Receptor Tyrosine Kinase	Protein Coding	445.92	Pathogenic ⁵ Likely pathogenic ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	22184391 18788887 12405914 (more) 15188137 11561161
3	NF1	Neurofibromin 1	Protein Coding	432.05	Pathogenic ⁵ Likely pathogenic ⁵ DISEASES inferred ¹⁴
4	CBL	Cbl Proto-Oncogene	Protein Coding	428.66	Pathogenic ⁵ Likely pathogenic ⁵ DISEASES inferred ¹⁴
5	DICER1	Dicer 1, Ribonuclease III	Protein Coding	423.83	Pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
6	PMS2	PMS1 Homolog 2, Mismatch Repair System Component	Protein Coding	420.28	Pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
7	MSH2	MutS Homolog 2	Protein Coding	420.09	Pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
8	MSH6	MutS Homolog 6	Protein Coding	419.94	Pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
9	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	414.74	Pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
10	PTEN	Phosphatase And Tensin Homolog	Protein Coding	413.77	Pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
11	BRCA1	BRCA1 DNA Repair Associated	Protein Coding	405.45	Pathogenic ⁵ DISEASES inferred ¹⁴
12	BRCA2	BRCA2 DNA Repair Associated	Protein Coding	405.25	Pathogenic ⁵ DISEASES inferred ¹⁴
13	SDHA	Succinate Dehydrogenase Complex Flavoprotein Subunit A	Protein Coding	404.11	Pathogenic ⁵ DISEASES inferred ¹⁴
14	LRRC56	Leucine Rich Repeat Containing 56	Protein Coding	400	Pathogenic ⁵
15	MIR206	MicroRNA 206	RNA Gene	364.22	Causal ⁴⁶ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	19710019
16	MIR29C	MicroRNA 29c	RNA Gene	354.28	Causal ⁴⁶ DISEASES inferred ¹⁴	18977326
17	MIR29B2	MicroRNA 29b-2	RNA Gene	350	Causal ⁴⁶	18977326
18	RMST	Rhabdomyosarcoma 2 Associated Transcript	RNA Gene	184.86	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications Gene name Summaries (show sections)	12082533
19	DDN-AS1	DDN And PRKAG1 Antisense RNA 1	RNA Gene	150	Experimental evidence: Expression ³⁷	27060091
20	NR2F1-AS1	NR2F1 Antisense RNA 1	RNA Gene	150	Experimental evidence: Expression ³⁷	27060091
21	FOXO1	Forkhead Box O1	Protein Coding	66.27	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Gene name Summaries Functions (show sections)	11672436 12196101 12456685 (more) 19408047 12606579 18303411 7536457 18094995 9479491 15492844
22	PAX3	Paired Box 3	Protein Coding	47.98	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Summaries (show sections)	15602708 9546061 15688409 (more) 17350164 19953635 15688035 10534762 15492844 10191090 9479491 18627422 8633043 11863357 15313887
23	PTCH1	Patched 1	Protein Coding	46.17	Likely pathogenic ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16294371 11130178 10719362 (more) 12204003 19020777 12845631
24	STIM1	Stromal Interaction Molecule 1	Protein Coding	45.79	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Summaries Proteins Functions (show sections)	9377559 10575208 11004585
25	PAX7	Paired Box 7	Protein Coding	45.54	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Summaries (show sections)	15688409 16892556 9479491 (more) 10534762 10828613 14706339 15492844
26	FGFR4	Fibroblast Growth Factor Receptor 4	Protein Coding	39.75	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	19809159 24124571
27	SLC22A18	Solute Carrier Family 22 Member 18	Protein Coding	39.06	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Summaries Pathways & Interactions (show sections)	9520460
28	FHL2	Four And A Half LIM Domains 2	Protein Coding	39.06	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Gene name Summaries Functions (show sections)
29	IGF2	Insulin Like Growth Factor 2	Protein Coding	31.92	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Summaries (show sections)	9771969 2177632 7499276 (more) 7686519 1315746 9502429 7981680 8116575 1312901 8040287 10224065 7527480 7577472 18788888 10534762 8909805 7728748 1434543 15090464 7514344 7794794 10884376 10935489 17519236 7923191 8054516 12942549 9136994 2315312 8073225 12234381
30	SDHC	Succinate Dehydrogenase Complex Subunit C	Protein Coding	30.08	Likely pathogenic ⁵ DISEASES inferred ¹⁴
31	MYOG	Myogenin	Protein Coding	28.49	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10095433 10666368 19372547 (more) 18493875 11007039 12783965 12426678 11688574 15536621 1313401 16010486 16979522 16720851 16220232 7547506 16514847 12944914 12760282 9836066 11473460 18708938 15630365 16082247 10853028 1341049 12218574
32	FOXO3	Forkhead Box O3	Protein Coding	27.76	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Gene name (show sections)	12196101
33	MYOD1	Myogenic Differentiation 1	Protein Coding	27.66	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19299559 2260621 8383879 (more) 12783965 1313401 7872424 9751114 12426678 11459700 11688574 9256013 16010486 9466584 12218574 9581851 16220232 12944914 12702724 1384962 9372238 12778001 10853028 1764365 16082247 10716945
34	NCOA1	Nuclear Receptor Coactivator 1	Protein Coding	25.18	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	19953635 15313887
35	MB	Myoglobin	Protein Coding	24.9	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	2119961 8065989 2166629 (more) 9990261 1373240 19483627 2323848 1752649 1664797
36	MYF6	Myogenic Factor 6	Protein Coding	22.2	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1764365
37	MDM2	MDM2 Proto-Oncogene	Protein Coding	22.12	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11742497 15634483 15024701 (more) 8221695 8751388 8644855 8756663 11244964 12481433 12702724 19454362 8117620 8686737 15098008 8261417 17938575 12574910
38	EWSR1	EWS RNA Binding Protein 1	Protein Coding	22.11	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	7882340
39	GLI1	GLI Family Zinc Finger 1	Protein Coding	21.98	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15024701 20152358 8221695 (more) 19454362 11948912
40	MYCN	MYCN Proto-Oncogene, BHLH Transcription Factor	Protein Coding	21.84	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11063797 11920742 8156531 (more) 9872655
41	IGF1R	Insulin Like Growth Factor 1 Receptor	Protein Coding	21.74	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8083365 18829562 11807989 (more) 9537584 7686519
42	MYF5	Myogenic Factor 5	Protein Coding	21.51	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19299559 12944914
43	TTN	Titin	Protein Coding	21.42	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Gene name (show sections)	9543674
44	VIM	Vimentin	Protein Coding	21.27	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1669003 2119961 7884590 (more) 9167712 1724320 1664797 7524332 15913431 17725305 9543674
45	ACTC1	Actin Alpha Cardiac Muscle 1	Protein Coding	20.73	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16010486 16220232 7884590 (more) 2231189 15913431
46	CDK4	Cyclin Dependent Kinase 4	Protein Coding	20.66	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15024701 8221695 19454362
47	FAM193B	Family With Sequence Similarity 193 Member B	Protein Coding	20.52	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Expressions (show sections)
48	IGFBP6	Insulin Like Growth Factor Binding Protein 6	Protein Coding	20.35	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	18039785 15914054
49	ENO2	Enolase 2	Protein Coding	20.17	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	2163356 2119961 1664797
50	MLH1	MutL Homolog 1	Protein Coding	20.08	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)

Sources

Variations for Rhabdomyosarcoma

ClinVar genetic disease variations for Rhabdomyosarcoma:

⁵ (show all 50)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	NF1	NM_001042492.3(NF1):c.4985G>A (p.Trp1662Ter)	SNV	Pathogenic	573015	rs1567611375	GRCh37: 17:29652987-29652987 GRCh38: 17:31325969-31325969
2	CBL	NM_005188.4(CBL):c.1259G>A (p.Arg420Gln)	SNV	Pathogenic	13810	rs267606708	GRCh37: 11:119149251-119149251 GRCh38: 11:119278541-119278541
3	NF1	NM_001042492.3(NF1):c.3826C>T (p.Arg1276Ter)	SNV	Pathogenic	237556	rs199474742	GRCh37: 17:29562746-29562746 GRCh38: 17:31235728-31235728
4	NF1	NM_001042492.3(NF1):c.5609G>A (p.Arg1870Gln)	SNV	Pathogenic	185354	rs786202112	GRCh37: 17:29654857-29654857 GRCh38: 17:31327839-31327839
5	HRAS, LRRC56	NM_005343.4(HRAS):c.35G>C (p.Gly12Ala)	SNV	Pathogenic	12603	rs104894230	GRCh37: 11:534288-534288 GRCh38: 11:534288-534288
6	ALK	NM_004304.5(ALK):c.3673G>A (p.Asp1225Asn)	SNV	Pathogenic	375886	rs1057519696	GRCh37: 2:29436920-29436920 GRCh38: 2:29214054-29214054
7	TP53	NM_000546.6(TP53):c.892G>T (p.Glu298Ter)	SNV	Pathogenic	93323	rs201744589	GRCh37: 17:7577046-7577046 GRCh38: 17:7673728-7673728
8	TP53	NM_000546.6(TP53):c.818G>A (p.Arg273His)	SNV	Pathogenic	12366	rs28934576	GRCh37: 17:7577120-7577120 GRCh38: 17:7673802-7673802
9	TP53	NM_000546.6(TP53):c.794T>C (p.Leu265Pro)	SNV	Pathogenic	245777	rs879253942	GRCh37: 17:7577144-7577144 GRCh38: 17:7673826-7673826
10	TP53	NM_000546.6(TP53):c.743G>A (p.Arg248Gln)	SNV	Pathogenic	12356	rs11540652	GRCh37: 17:7577538-7577538 GRCh38: 17:7674220-7674220
11	TP53	NM_000546.6(TP53):c.730G>A (p.Gly244Ser)	SNV	Pathogenic	376600	rs1057519989	GRCh37: 17:7577551-7577551 GRCh38: 17:7674233-7674233
12	TP53	NM_000546.6(TP53):c.473G>A (p.Arg158His)	SNV	Pathogenic	141963	rs587782144	GRCh37: 17:7578457-7578457 GRCh38: 17:7675139-7675139
13	TP53	NM_000546.6(TP53):c.451C>T (p.Pro151Ser)	SNV	Pathogenic	12370	rs28934874	GRCh37: 17:7578479-7578479 GRCh38: 17:7675161-7675161
14	TP53	NM_000546.6(TP53):c.451C>A (p.Pro151Thr)	SNV	Pathogenic	12369	rs28934874	GRCh37: 17:7578479-7578479 GRCh38: 17:7675161-7675161
15	TP53	NM_000546.6(TP53):c.375G>A (p.Thr125=)	SNV	Pathogenic	177825	rs55863639	GRCh37: 17:7579312-7579312 GRCh38: 17:7675994-7675994
16	TP53	NM_000546.6(TP53):c.365_366del (p.Val122fs)	MICROSAT	Pathogenic	127809	rs587780067	GRCh37: 17:7579321-7579322 GRCh38: 17:7676003-7676004
17	NF1	NM_001042492.3(NF1):c.1466A>G (p.Tyr489Cys)	SNV	Pathogenic	354	rs137854557	GRCh37: 17:29541542-29541542 GRCh38: 17:31214524-31214524
18	NF1	NM_001042492.3(NF1):c.2041C>T (p.Arg681Ter)	SNV	Pathogenic	188280	rs768638173	GRCh37: 17:29553492-29553492 GRCh38: 17:31226474-31226474
19	NF1	NM_001042492.3(NF1):c.5305C>T (p.Arg1769Ter)	SNV	Pathogenic	228381	rs876657714	GRCh37: 17:29654553-29654553 GRCh38: 17:31327535-31327535
20	NF1	NM_001042492.3(NF1):c.6704+1G>T	SNV	Pathogenic	547680	rs1060500376	GRCh37: 17:29664899-29664899 GRCh38: 17:31337881-31337881
21	NF1	NM_001042492.3(NF1):c.7153AACTTT[1] (p.2385NF[1])	MICROSAT	Pathogenic	220715	rs864622639	GRCh37: 17:29670116-29670121 GRCh38: 17:31343098-31343103
22	HRAS, LRRC56	NM_005343.4(HRAS):c.34G>A (p.Gly12Ser)	SNV	Pathogenic	12602	rs104894229	GRCh37: 11:534289-534289 GRCh38: 11:534289-534289
23	DICER1	NM_177438.3(DICER1):c.2026C>T (p.Arg676Ter)	SNV	Pathogenic	242054	rs878855246	GRCh37: 14:95579443-95579443 GRCh38: 14:95113106-95113106
24	DICER1	NM_177438.3(DICER1):c.1174C>T (p.Arg392Ter)	SNV	Pathogenic	429141	rs1131691211	GRCh37: 14:95590735-95590735 GRCh38: 14:95124398-95124398
25	MSH2	NM_000251.3(MSH2):c.1147C>T (p.Arg383Ter)	SNV	Pathogenic	90554	rs63749849	GRCh37: 2:47656951-47656951 GRCh38: 2:47429812-47429812
26	MSH6	NM_000179.3(MSH6):c.2300C>T (p.Thr767Ile)	SNV	Pathogenic	141058	rs587781462	GRCh37: 2:48027422-48027422 GRCh38: 2:47800283-47800283
27	PMS2	NM_000535.7(PMS2):c.2404C>T (p.Arg802Ter)	SNV	Pathogenic	9237	rs63751466	GRCh37: 7:6017260-6017260 GRCh38: 7:5977629-5977629
28	BRCA2	NM_000059.4(BRCA2):c.462_463del (p.Arg155_Asp156insTer)	DEL	Pathogenic	51684	rs80359459	GRCh37: 13:32900273-32900274 GRCh38: 13:32326136-32326137
29	BRCA2	NM_000059.4(BRCA2):c.3103G>T (p.Glu1035Ter)	SNV	Pathogenic	51400	rs80358556	GRCh37: 13:32911595-32911595 GRCh38: 13:32337458-32337458
30	BRCA2	NM_000059.4(BRCA2):c.3599_3600del (p.Asp1199_Cys1200insTer)	DEL	Pathogenic	51493	rs80359391	GRCh37: 13:32912090-32912091 GRCh38: 13:32337953-32337954
31	BRCA2	NM_000059.4(BRCA2):c.3847_3848del (p.Val1283fs)	DEL	Pathogenic	37859	rs80359405	GRCh37: 13:32912338-32912339 GRCh38: 13:32338201-32338202
32	BRCA2	NM_000059.4(BRCA2):c.7133C>G (p.Ser2378Ter)	SNV	Pathogenic	38085	rs276174889	GRCh37: 13:32929123-32929123 GRCh38: 13:32354986-32354986
33	BRCA2	NM_000059.4(BRCA2):c.7857G>A (p.Trp2619Ter)	SNV	Pathogenic	38122	rs80359011	GRCh37: 13:32936711-32936711 GRCh38: 13:32362574-32362574
34	SDHA	NM_004168.4(SDHA):c.2T>G (p.Met1Arg)	SNV	Pathogenic	422382	rs750380279	GRCh37: 5:218472-218472 GRCh38: 5:218357-218357
35	SDHA	NM_004168.4(SDHA):c.91C>T (p.Arg31Ter)	SNV	Pathogenic	142601	rs142441643	GRCh37: 5:223624-223624 GRCh38: 5:223509-223509
36	BRCA1	NM_007294.4(BRCA1):c.5177_5180del (p.Arg1726fs)	MICROSAT	Pathogenic	37644	rs80357867	GRCh37: 17:41215363-41215366 GRCh38: 17:43063346-43063349
37	PTEN	NM_000314.8(PTEN):c.388C>T (p.Arg130Ter)	SNV	Pathogenic	7819	rs121909224	GRCh37: 10:89692904-89692904 GRCh38: 10:87933147-87933147
38	BRCA1	NM_007294.4(BRCA1):c.844_850dup (p.Gln284fs)	DUP	Pathogenic	55735	rs80357989	GRCh37: 17:41246697-41246698 GRCh38: 17:43094680-43094681
39	SDHC	NM_003001.5(SDHC):c.386G>A (p.Trp129Ter)	SNV	Likely Pathogenic	978229	rs1672294906	GRCh37: 1:161326611-161326611 GRCh38: 1:161356821-161356821
40	PTCH1	NM_001083603.3(PTCH1):c.93C>G (p.Tyr31Ter)	SNV	Likely Pathogenic	978808	rs756069384	GRCh37: 9:98279010-98279010 GRCh38: 9:95516728-95516728
41	TP53	NM_000546.6(TP53):c.560-1G>C	SNV	Likely Pathogenic	492748	rs1202793339	GRCh37: 17:7578290-7578290 GRCh38: 17:7674972-7674972
42	NF1	NM_001042492.3(NF1):c.3520C>T (p.Gln1174Ter)	SNV	Likely Pathogenic	978806	rs868450405	GRCh37: 17:29560043-29560043 GRCh38: 17:31233025-31233025
43	FGFR4	NM_213647.3(FGFR4):c.1605C>G (p.Asn535Lys)	SNV	Likely Pathogenic	376150	rs1057519792	GRCh37: 5:176522416-176522416 GRCh38: 5:177095415-177095415
44	FGFR4	NM_213647.3(FGFR4):c.1649T>A (p.Val550Glu)	SNV	Likely Pathogenic	376151	rs1057519793	GRCh37: 5:176522552-176522552 GRCh38: 5:177095551-177095551
45	FGFR4	NM_213647.3(FGFR4):c.1605C>A (p.Asn535Lys)	SNV	Likely Pathogenic	376149	rs1057519792	GRCh37: 5:176522416-176522416 GRCh38: 5:177095415-177095415
46	CBL	NM_005188.4(CBL):c.1495C>T (p.Arg499Ter)	SNV	Likely Pathogenic	978807	rs778927765	GRCh37: 11:119155742-119155742 GRCh38: 11:119285032-119285032
47	ALK	NM_004304.5(ALK):c.4298_4299del (p.Glu1433fs)	DEL	Likely Pathogenic	978809	rs1668950344	GRCh37: 2:29416654-29416655 GRCh38: 2:29193788-29193789
48	TP53	NM_000546.6(TP53):c.704A>G (p.Asn235Ser)	SNV	Uncertain Significance	127821	rs144340710	GRCh37: 17:7577577-7577577 GRCh38: 17:7674259-7674259
49	BRCA2	NM_000059.4(BRCA2):c.9874C>T (p.Pro3292Ser)	SNV	Uncertain Significance	234197	rs876660917	GRCh37: 13:32972524-32972524 GRCh38: 13:32398387-32398387
50	PIK3CA	NM_006218.4(PIK3CA):c.1375_1386del (p.Ile459_Thr462del)	DEL	Not Provided	1327587		GRCh37: 3:178928095-178928106 GRCh38: 3:179210307-179210318

Cosmic variations for Rhabdomyosarcoma:

⁸ (show top 50) (show all 619)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM93183630	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.743G>A	p.R248Q	17:7674220-7674220	4
2	COSM106065628	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.394A>G	p.K132E	17:7675218-7675218	4
3	COSM112255322	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.637C>T	p.R213*	17:7674894-7674894	4
4	COSM122271658	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.337G>T	p.G113C	17:7674230-7674230	4
5	COSM145017865	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.616G>A	p.G206S	17:7674230-7674230	4
6	COSM142605762	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.754A>C	p.K252Q	17:7673749-7673749	4
7	COSM144013587	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.700G>A	p.G234S	17:7674230-7674230	4
8	COSM144650760	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.701G>A	p.R234H	17:7673802-7673802	4
9	COSM122271355	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.305A>G	p.Y102C	17:7674262-7674262	4
10	COSM143576669	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.551C>G	p.P184R	17:7674863-7674863	4
11	COSM106096066	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.871A>C	p.K291Q	17:7673749-7673749	4
12	COSM145017326	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.407G>A	p.R136H	17:7675088-7675088	4
13	COSM144544530	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.494A>G	p.E165G	17:7674920-7674920	4
14	COSM144025238	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.361A>G	p.K121E	17:7675218-7675218	4
15	COSM144020071	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.695T>C	p.M232T	17:7674235-7674235	4
16	COSM112297123	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.871A>C	p.K291Q	17:7673749-7673749	4
17	COSM93183307	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.524G>A	p.R175H	17:7675088-7675088	4
18	COSM144015364	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.604C>T	p.R202*	17:7674894-7674894	4
19	COSM143371076	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.616G>A	p.G206S	17:7674230-7674230	4
20	COSM142845635	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.961A>T	p.K321*	17:7673567-7673567	4
21	COSM87906219	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.728T>C	p.M243T	17:7674235-7674235	4
22	COSM105633282	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.394A>G	p.K132E	17:7675218-7675218	4
23	COSM93229090	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.871A>C	p.K291Q	17:7673749-7673749	4
24	COSM145024780	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.611T>C	p.M204T	17:7674235-7674235	4
25	COSM121884328	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.332T>C	p.M111T	17:7674235-7674235	4
26	COSM121878773	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.241C>T	p.R81*	17:7674894-7674894	4
27	COSM105622516	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.637C>T	p.R213*	17:7674894-7674894	4
28	COSM143386796	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.134A>G	p.E45G	17:7674920-7674920	4
29	COSM93183281	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.818G>A	p.R273H	17:7673802-7673802	4
30	COSM112446896	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.739A>G	p.N247D	17:7674224-7674224	4
31	COSM122105750	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.272C>G	p.P91R	17:7674863-7674863	4
32	COSM142838784	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.637C>T	p.R213*	17:7674894-7674894	4
33	COSM143984574	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.394A>C	p.K132Q	17:7673749-7673749	4
34	COSM143946062	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.160C>T	p.R54*	17:7674894-7674894	4
35	COSM143943565	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.47G>A	p.R16H	17:7675088-7675088	4
36	COSM144320480	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.277A>G	p.K93E	17:7675218-7675218	4
37	COSM144651337	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.616G>A	p.G206S	17:7674230-7674230	4
38	COSM145221104	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.551C>G	p.P184R	17:7674863-7674863	4
39	COSM144120969	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.394A>C	p.K132Q	17:7673749-7673749	4
40	COSM122781709	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.475A>C	p.K159Q	17:7673749-7673749	4
41	COSM112253106	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.818G>A	p.R273H	17:7673802-7673802	4
42	COSM111802670	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.871A>C	p.K291Q	17:7673749-7673749	4
43	COSM88149182	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.668C>G	p.P223R	17:7674863-7674863	4
44	COSM142570943	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.844A>T	p.K282*	17:7673567-7673567	4
45	COSM105620276	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.743G>A	p.R248Q	17:7674220-7674220	4
46	COSM142837352	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.743G>A	p.R248Q	17:7674220-7674220	4
47	COSM106059837	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.728T>C	p.M243T	17:7674235-7674235	4
48	COSM87949760	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.871A>C	p.K291Q	17:7673749-7673749	4
49	COSM143413354	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.754A>C	p.K252Q	17:7673749-7673749	4
50	COSM144182541	TP53	soft tissue,striated muscle,rhabdomyosarcoma,NS	c.706A>G	p.N236D	17:7674224-7674224	4

Copy number variations for Rhabdomyosarcoma from CNVD:

⁶ (show all 19)

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	32214	1	34600000	40100000	Amplification	MYCL	Rhabdomyosarcoma
2	48341	11	1	2800000	Loss	HRAS	Rhabdomyosarcoma
3	55467	11	532242	535550	Mutation	HRAS	Rhabdomyosarcoma
4	69397	12	54900000	58100000	Amplification or loss	GLI1	Rhabdomyosarcoma
5	69949	12	56600000	58100000	Amplification	CDK4	Rhabdomyosarcoma
6	69950	12	56600000	58100000	Amplification	TSPAN31	Rhabdomyosarcoma
7	79876	13	79000000	101700000	Amplification	MIR17HG	Rhabdomyosarcoma
8	79877	13	79000000	101700000	Amplification	GPC5	Rhabdomyosarcoma
9	106840	17	1	3300000	Loss	HIC1	Rhabdomyosarcoma
10	106842	17	1	3300000	Loss		Rhabdomyosarcoma
11	106969	17	10700000	22200000	Loss		Rhabdomyosarcoma
12	110141	17	314735	515143	Loss		Rhabdomyosarcoma
13	127361	19	32400000	43400000	Amplification	AKT2	Rhabdomyosarcoma
14	185187	4	187100000	191154276	Loss		Rhabdomyosarcoma
15	187611	4	52700000	59500000	Loss	PDGFRA	Rhabdomyosarcoma
16	187815	4	55095264	55146925	Amplificationlication	PDGFRA	Rhabdomyosarcoma
17	187856	4	55524095	55606879	Amplificationlication	KIT	Rhabdomyosarcoma
18	239020	8	36500000	45600000	Amplification	FGFR1	Rhabdomyosarcoma
19	253524	9	43600000	47300000	Loss		Rhabdomyosarcoma

Sources

Expression for Rhabdomyosarcoma

Search GEO for disease gene expression data for Rhabdomyosarcoma.

Sources

Pathways for Rhabdomyosarcoma

Pathways directly related to Rhabdomyosarcoma:

#	Pathway	Source
1	Defective SLC22A18 causes lung cancer (LNCR) and embryonal rhabdomyosarcoma 1 (RMSE1)	Reactome ⁶⁶

Pathways related to Rhabdomyosarcoma according to GeneCards Suite gene sharing:

(show all 25)

#	Super pathways	Score	Top Affiliating Genes
1	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.58	TP53 PTEN PMS2 NF1 MSH6 MSH2
2	Prolactin Signaling ⁶⁴ Show member pathways Development Prolactin receptor signaling ²² EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ⁷⁴ ErbB Family Pathway ⁶⁴ ErbB signaling pathway ⁷⁴ ErbB2-ErbB3 Heterodimers ⁶⁴ ErbB4 Pathway ⁶⁴ Estrogen-stimulated signaling through PRKCZ ⁶⁶ Glioblastoma Multiforme ⁶⁴ Glioblastoma signaling pathways ⁷⁴ Growth Hormone Signaling ⁶⁴ HMGB1 Pathway ⁶⁴ IL-2 Pathway ⁶⁴ LPS Stimulated MAPK Signaling ⁶⁴ PACAP Signaling ⁶⁴ PI3K Signaling in B-Lymphocyte ⁶⁴ TCA cycle nutrient use and invasiveness of ovarian cancer ⁷⁴ Thrombopoietin Pathway ⁶⁴ TREM1 Pathway ⁶⁴ UVA-Induced MAPK Signaling ⁶⁴ UVB-Induced MAPK Signaling ⁶⁴ UVC-Induced MAPK Signaling ⁶⁴	13.35	TP53 PTEN NF1 MSH6 HRAS CBL
3	Homology Directed Repair ⁶⁶ Show member pathways Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex ⁶⁶ DNA Double-Strand Break Repair ⁶⁶ DNA Repair ⁶⁶ G2/M DNA damage checkpoint ⁶⁶ HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) ⁶⁶ HDR through MMEJ (alt-NHEJ) ⁶⁶ Processing of DNA double-strand break ends ⁶⁶	13.08	TP53 PMS2 MSH6 MSH2 BRCA2 BRCA1
4	TCR Signaling (Qiagen) ⁶⁴ Show member pathways Fc-EpsilonRI Pathway ⁶⁴ ITK and TCR Signaling ⁶⁴ PDGF Pathway ⁶⁴ PKC-Theta Pathway ⁶⁴	12.76	TP53 MSH6 MSH2 HRAS BRCA2 BRCA1
5	Homologous DNA Pairing and Strand Exchange ⁶⁶ Show member pathways Defective Base Excision Repair Associated with NEIL1 ⁶⁶ Defective homologous recombination repair (HRR) due to BRCA2 loss of function ⁶⁶ Diseases of Base Excision Repair ⁶⁶ Diseases of DNA Double-Strand Break Repair ⁶⁶ Diseases of DNA repair ⁶⁶ Fanconi anemia pathway ⁶¹ Fanconi Anemia Pathway ⁶⁶ HDR through Homologous Recombination (HRR) ⁶⁶ HDR through Single Strand Annealing (SSA) ⁶⁶ Impaired BRCA2 binding to RAD51 ⁶⁶ Presynaptic phase of homologous DNA pairing and strand exchange ⁶⁶	12.63	PMS2 MSH6 MSH2 BRCA2 BRCA1
6	DNA repair pathways, full network ⁷⁴ Show member pathways Defective Mismatch Repair Associated With MSH2 ⁶⁶ Defective Mismatch Repair Associated With MSH3 ⁶⁶ Defective Mismatch Repair Associated With MSH6 ⁶⁶ Diseases of Mismatch Repair (MMR) ⁶⁶ Dual Incision in GG-NER ⁶⁶ Homologous recombination ⁷⁴ Mismatch Repair ⁶⁶ Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) ⁶⁶ Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) ⁶⁶ Non-homologous end joining ⁷⁴ Nucleotide excision repair ⁷⁴ Nucleotide excision repair in xeroderma pigmentosum ⁷⁴ Nucleotide Excision Repair Pathway ⁶⁴	12.49	PMS2 MSH6 MSH2 BRCA2 BRCA1
7	Chks in Checkpoint Regulation ⁶⁴ Show member pathways DNA Repair Mechanisms ⁶⁴ Estrogen-mediated S-Phase Entry ⁶⁴ G2-M Phase Transition ⁶⁴ SREBP Proteolysis ⁶⁴	12.48	TP53 MSH6 MSH2 BRCA2 BRCA1
8	DNA Damage ³	12.35	TP53 MSH6 MSH2 BRCA2 BRCA1
9	Base excision repair ⁷⁴ Show member pathways Abasic sugar-phosphate removal via the single-nucleotide replacement pathway ⁶⁶ APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway ⁶⁶ Cell cycle Transition and termination of DNA replication ²² Displacement of DNA glycosylase by APEX1 ⁶⁶ DNA mismatch repair ⁷⁴ Gap-filling DNA repair synthesis and ligation in GG-NER ⁶⁶ Mismatch Repair in Eukaryotes ⁶⁴ PCNA-Dependent Long Patch Base Excision Repair ⁶⁶ POLB-Dependent Long Patch Base Excision Repair ⁶⁶ Resolution of Abasic Sites (AP sites) ⁶⁶ Resolution of AP sites via the multiple-nucleotide patch replacement pathway ⁶⁶ Resolution of AP sites via the single-nucleotide replacement pathway ⁶⁶	12.3	PMS2 MSH6 MSH2 BRCA1
10	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.26	TP53 PTEN HRAS BRCA2 BRCA1
11	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	12.01	TP53 PTEN HRAS CBL
12	Direct p53 effectors ⁶¹	11.9	MSH2 PMS2 PTEN TP53
13	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	11.9	TP53 PTEN NF1 MSH6 MSH2 HRAS
14	Senescence and autophagy in cancer ⁷⁴	11.82	TP53 PTEN HRAS
15	DNA damage response (only ATM dependent) ⁷⁴	11.8	TP53 PTEN HRAS
16	DNA IR-double strand breaks and cellular response via ATM ⁷⁴ Show member pathways ATM pathway ⁶¹ DNA damage_DNA-damage-induced responses ²²	11.78	TP53 BRCA2 BRCA1
17	Retinoblastoma gene in cancer ⁷⁴	11.71	TP53 MSH6 MIR29B2
18	Integrated breast cancer pathway ⁷⁴	11.68	TP53 PTEN NF1 MSH6 MSH2 BRCA2
19	Head and neck squamous cell carcinoma ⁷⁴	11.62	TP53 PTEN HRAS
20	DNA IR-damage and cellular response via ATR ⁷⁴	11.58	TP53 MSH2 BRCA2 BRCA1
21	BRCA1 Pathway ⁶⁴ Show member pathways Fanconi's Anaemia Pathway ⁶⁴	11.57	TP53 MSH6 MSH2 BRCA2 BRCA1
22	BDNF-TrkB signaling ⁷⁴ Show member pathways Synaptic signaling pathways associated with autism spectrum disorder ⁷⁴	11.52	HRAS NF1 PTEN
23	Pathways affected in adenoid cystic carcinoma ⁷⁴	11.42	BRCA1 HRAS PTEN TP53
24	Integrated cancer pathway ⁷⁴	11.13	TP53 PTEN MSH6 MSH2 BRCA1
25	Platinum Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰	11.1	PMS2 MSH6 MSH2

Sources

GO Terms for Rhabdomyosarcoma

Cellular components related to Rhabdomyosarcoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mismatch repair complex	GO:0032300	9.33	PMS2 MSH2
2	nuclear ubiquitin ligase complex	GO:0000152	9.26	BRCA2 BRCA1
3	MutSalpha complex	GO:0032301	8.92	MSH6 MSH2

Biological processes related to Rhabdomyosarcoma according to GeneCards Suite gene sharing:

(show all 20)

#	Name	GO ID	Score	Top Affiliating Genes
1	regulation of cell cycle	GO:0051726	10.15	BRCA1 HRAS MSH2 PTEN TP53
2	negative regulation of gene expression	GO:0010629	10.12	TP53 MIR29C MIR206 HRAS DICER1
3	cellular response to ionizing radiation	GO:0071479	10.01	TP53 BRCA2 BRCA1
4	fibroblast proliferation	GO:0048144	9.99	TP53 NF1 HRAS
5	stem cell proliferation	GO:0072089	9.98	TP53 NF1 BRCA2
6	intrinsic apoptotic signaling pathway	GO:0097193	9.95	TP53 MSH6 HRAS
7	intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	GO:0042771	9.93	BRCA2 MSH2 TP53
8	double-strand break repair	GO:0006302	9.92	BRCA1 BRCA2 MSH2 TP53
9	mismatch repair	GO:0006298	9.91	PMS2 MSH6 MSH2
10	negative regulation of Schwann cell proliferation	GO:0010626	9.89	NF1 DICER1
11	response to gamma radiation	GO:0010332	9.88	TP53 CBL BRCA2
12	positive regulation of helicase activity	GO:0051096	9.87	MSH6 MSH2
13	determination of adult lifespan	GO:0008340	9.85	TP53 MSH6 MSH2
14	somatic recombination of immunoglobulin gene segments	GO:0016447	9.8	MSH6 MSH2
15	chordate embryonic development	GO:0043009	9.73	BRCA2 BRCA1
16	response to X-ray	GO:0010165	9.73	TP53 MSH2 BRCA2
17	maintenance of DNA repeat elements	GO:0043570	9.7	MSH6 MSH2
18	somatic hypermutation of immunoglobulin genes	GO:0016446	9.63	PMS2 MSH6 MSH2
19	intrinsic apoptotic signaling pathway in response to DNA damage	GO:0008630	9.43	MSH6 MSH2 BRCA2 BRCA1
20	cellular response to DNA damage stimulus	GO:0006974	9.32	TP53 PMS2 MSH6 MSH2 CBL BRCA2

Molecular functions related to Rhabdomyosarcoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	MutLalpha complex binding	GO:0032405	9.71	MSH6 MSH2
2	oxidized purine DNA binding	GO:0032357	9.67	MSH6 MSH2
3	guanine/thymine mispair binding	GO:0032137	9.62	MSH6 MSH2
4	single guanine insertion binding	GO:0032142	9.56	MSH6 MSH2
5	single thymine insertion binding	GO:0032143	9.46	MSH6 MSH2
6	ATP-dependent DNA damage sensor activity	GO:0140664	9.43	PMS2 MSH6 MSH2
7	mismatched DNA binding	GO:0030983	9.02	PMS2 MSH6 MSH2